

[54] PROCESSES FOR THE PREPARATION OF DELAYED ACTION AND PROGRAMMED RELEASE PHARMACEUTICAL FORMS AND MEDICAMENTS OBTAINED THEREBY

[75] Inventors: Donald Panoz, Tuckerstown, Bermuda; Gilbert Corneille, Paris, France

[73] Assignee: Elan Corp., P.L.C., Monksland, Ireland

[21] Appl. No.: 933,287

[22] Filed: Nov. 18, 1986

Related U.S. Application Data

[63] Continuation of Ser. No. 559,431, Dec. 8, 1983, abandoned, which is a continuation-in-part of Ser. No. 287,722, Jul. 24, 1981, abandoned.

[30] Foreign Application Priority Data

Dec. 7, 1979 [FR] France 79 30085

[51] Int. Cl.⁵ A61K 9/22; A61K 9/26; A61K 9/16

[52] U.S. Cl. 424/468; 424/469; 424/489

[58] Field of Search 424/468, 469, 489

[56] References Cited

U.S. PATENT DOCUMENTS

443,428	4/1984	Oshlack et al.	424/21
2,971,889	2/1961	Swintosky	167/82
2,993,836	7/1961	Nash et al.	147/82
3,136,692	6/1964	Bandelin	424/44
3,247,066	4/1966	Milosovich	167/82
3,330,729	7/1967	Johnson	167/82
3,499,959	3/1970	Corn	424/32
3,520,970	7/1970	Lehmann	424/25
3,538,214	11/1970	Polli et al.	424/81
3,557,279	1/1971	Morse	424/20
3,608,063	9/1971	Banker	424/22
3,629,393	12/1971	Nakamoto et al.	424/22
3,634,584	1/1972	Poole	424/21
3,653,914	4/1972	Schmitt et al.	424/44
3,676,549	7/1972	Huguchi et al.	424/44
3,764,668	10/1973	Higuchi et al.	424/44
3,835,221	9/1974	Fulberth et al.	424/20
3,882,228	5/1975	Boncey et al.	424/44
3,883,648	5/1975	Ross et al.	424/44
3,885,027	5/1975	Shaw et al.	424/44
3,917,813	11/1975	Pederson	424/20
3,954,959	5/1976	Pederson	424/21
3,961,041	6/1976	Nishimura et al.	424/44
4,079,125	3/1978	Sipos	424/35
4,083,949	4/1978	Benedikt	424/19
4,173,626	11/1979	Dempski et al.	424/19
4,181,708	1/1980	Dannelly	424/19
4,196,187	4/1980	Dannelly	424/21
4,199,560	4/1980	Gyarmati	424/19

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

106443	8/1982	European Pat. Off.
2336218	2/1975	Fed. Rep. of Germany
2741755	3/1978	Fed. Rep. of Germany
2950977	12/1978	Fed. Rep. of Germany
2743183	4/1979	Fed. Rep. of Germany
M7392	12/1969	France
2223047	10/1974	France
2353285	12/1977	France

(List continued on next page.)

OTHER PUBLICATIONS

Gibaldi, M.: Biopharmaceutics and Clinical Pharmacokinetics. Lea and Febiger, Philadelphia, 1977 (2nd Ed.).
 Harris, P.A. and Riegelman, S.: J. Pharm. Sci., 58(1):71, 1969.
 Gibaldi, M., Boyes, R.N. and Feldman, S.: J. Pharm. Sci., 60(9):1338, 1971.
 Scheline, R.R.: Pharmacol. Rev., 25(4):451, 1973.
 Conolly, M.E., Davies, D.S., Dollery, C.T., et al.: Br. J. Pharmac., 46:458, 1972.
 Brunk, S.F., and Delle, M.: Clin. Pharmacol. Ther., 16(1):51, 1974.
 Gibaldi, M. and Perrier, D.: Drug Metab. Rev., 3(2):185, 1974.
 Goldman, P.: N. Engl. J. Med., 289(12):623, 1973.
 Shand, D.G. and Rangno, R.E.: Pharmacol., 7:159, 1972.
 Paterson, J.W., Conolly, M.E., Dollery, C.T., Hayes, A. and Cooper, R.G.: Pharmacol. Clin., 2:127, 1970.
 Evans, G.H. and Shand, D.G.: Clin. Pharmacol. Ther., 14(4):494, 1973.
 Nies, A.S. and Shand, D.G.: Circulation, 52:6, 1975.
 Regårdh, C.G., Borg, K.O., Johansson, R., Johansson, G., and Palmer, L.: J. Pharmacokin. Biopharm., 2(4):347, 1974.
 Gibaldi, M.: J. Pharm. Sci., 64(6):1035, 1975.

(List continued on next page.)

Primary Examiner—Frederick E. Waddell
Attorney, Agent, or Firm—Robert H. Falk; Henry Croskell; Harry J. Watson

[57] ABSTRACT

Specifically, the present invention relates to processes for preparing delayed action galenic forms. The process is characterized in that the application solutions of excipients, coatings and active constituents are adjusted to a desired pH. The independence of the rate of dissolution of a controlled release or sustained action oral pharmaceutical form is increased by admixing a pH adjusting agent with every application solution of medicament, excipient or coating, throughout the course of formulation of the pharmaceutical form.

16 Claims, 10 Drawing Sheets

U.S. PATENT DOCUMENTS

4,206,214	6/1980	Harker et al.	424/251
4,248,872	2/1981	Horrobin	424/251
4,261,969	1/1981	Heller	424/19
4,265,874	5/1981	Bonsen et al.	424/44
4,267,138	5/1981	Dobo et al.	264/117
4,289,751	9/1981	Windheuser et al.	424/44
4,341,563	7/1982	Kurihara et al.	106/71
4,341,759	7/1982	Bogentoft et al.	424/21
4,344,929	8/1982	Bonsen et al.	424/44
4,361,546	11/1982	Stricker	424/19
4,367,217	1/1983	Gruber et al.	424/19
4,427,648	1/1984	Brickl	424/16
4,432,965	2/1984	Keith et al.	424/19
4,434,152	2/1984	Horvath et al.	424/19
4,459,279	7/1984	Stricker et al.	424/19
4,460,563	7/1984	Calachi	424/35
4,483,846	1/1984	Koide et al.	424/19
4,499,093	2/1985	Galabov et al.	514/258
4,521,401	6/1985	Dunn	424/19
4,572,833	2/1986	Pederson et al.	424/20
4,578,264	3/1986	Stricker et al.	424/37
4,606,909	8/1986	Bechgaard et al.	424/21
4,663,150	5/1987	Panoz et al.	424/494
4,713,248	12/1987	Kjorn et al.	424/468
4,716,040	12/1987	Panoz	424/497
4,716,041	12/1987	Kjornaes et al.	424/468
4,721,619	12/1987	Panoz	424/459
4,726,951	12/1987	PANOZ	424/465

FOREIGN PATENT DOCUMENTS

2390959	12/1978	France
2401619	3/1979	France
862376	3/1961	United Kingdom
1139869	1/1969	United Kingdom
1139991	1/1969	United Kingdom
1510370	5/1978	United Kingdom
2025227A	1/1980	United Kingdom
2039737	8/1980	United Kingdom
2067073A	7/1981	United Kingdom

OTHER PUBLICATIONS

- Wilkinson, G.R. and Shand, D.G.: *Clin. Pharmacol. Ther.*, 18(4):377, 1975.
- Woodcock, B.G., Loh, W., Habedank, W. and Rietbrock, N.: *Clin. Pharmacol. Ther.*, 32(5):622, 1982.
- Assinder, D.F., Chasseaud, L.F., Hunter, J.O., Jung, R.J., and Taylor, T. *Arzneim Forsch./Drug Res.*, 27:156, 1977.
- Assinder, D.F., Chasseaud, L.F. and Taylor, T.: *J. Pharm. Sci.*, 66(6):775, 1977.
- Zylber-Katz, E., Koren, G., Granit, L. and Levy, M.: *Biopharm. Drug Dis.*, 5:109, 1984.
- Woodcock, B.G., Schulz, W., Kober, G. and Rietbrock, N.: *Clin. Pharmacol. Ther.*, 30(1):52, 1981.
- Gilmore, I.T. and Hoffman, A.F.: *Gastroenterology*, 78(1):177, 1980.
- Ueda, C.T., Williamson, B.J. and Dzindzio, B.S.: *Clin. Pharmacol. Ther.*, 20(3):260, 1978.
- Levy, G., Leonards, J.R., and Procknal, J.A.: *J. Pharm. Sci.*, 54(12):1719, 1965.
- Nelson, E.: *J. Am. Pharm. Assoc. (Sci. ed.)*, XLVII(4):297, 1958.
- Juncher, H. and Raaschou, F.: *AM&CT*, IV(9):497, 1957.
- Anderson, K.W.: *Arch. Int. Pharmacodyn.*, 147(1-2):171, 1964.
- Epstein, L.C. and Lasagna, L.: *J. Pharmacol. Exp. Ther.*, 164(2):433, 1968.
- Hogben, C.A.M., Schanker, L.S., Tocco, D.J. et al.: *J. Pharmacol. Exp. Ther.*, 120:540, 1957.
- Schanker, L.S.: *J. Med. Pharm. Chem.*, 2(4):343, 1960.
- Hogben, C.Q.M., Tocco, D.J., Brodie, B.B., et al.: *J. Pharmacol. Exp. Ther.*, 125:275, 1959.
- Shore, P.A., Brodie, B.B., Hogben, C.A.M.: *J. Pharmacol. Exp. Ther.*, 119:361, 1957.
- Travell, J.: *J. Pharmacol. Exp. Ther.*, 69:21, 1940.
- Bradley, W.B., Schnedorf, J.G. and Ivey, A.C.: *Am. J. Digest. Dis. & Nut.*, 3:415, 1936.
- Schanker, L.S., Tocco, D.J., Brodie, B.B., et al.: *J. Pharmacol. Exp. Ther.*, 123:81, 1958.
- Levine, R.R.: *Digest. Dis.*, 15(2):171, 1970.
- Truitt, E.B., Jr. and Morgan, A.M.: *J. Pharm. Sci.*, 53(2):129, 1964.
- Barr, W.H., Adir, J. and Garrettson, L.: *Clin. Pharmacol. Ther.*, 12(5):779, 1971.
- Lim, C.C., Presbury, D.G.C. and Adamson, J.: *Practitioner*, 212:728, 1974.
- Manners, B.T.B., Grob, P.R. and Gibbs, J.: *Brit. J. Clin. Practice*, 26(3):129, 1972.
- Pines, A., Greenfield, J.S.B., Raafat, H., Sreedharan, K.S., Khaja G. and Linsell, W.D.: *Brit. J. Clin. Practice*, 26(10):475, 1972.
- Perera, P.M.: *Brit. J. Vener. Dis.*, 51:333, 1975.
- Lucas, C.R., Mugglestone, C.J. and Thomas D.R.: *J. Int. Med. Res.*, 5:124, 1977.
- Corrigan, O.I., Dunne, A. McLaughlin, J., Geoghegan, E.J., Killian, C.A. and Panoz, D.E.: p. 163. *Marcel Dekker, Inc.*, New York and Basel, 1983.
- Siurala, M., et al.: *Scand. J. Gastroent.*, 4:269, 1969.
- George, C.F.: *Clin. Pharmacokin.*, 4:433, 1979.
- Chasseaud, L.F., Down, W.H. and Grundy, R.K.: *Europ. J. Clin. Pharmacol.*, 8:157, 1975.
- Smith, S.S. and Rawlins, M.D.: *Variability in Human Drug Response*. Butterworths and Co., London, 1976 (2nd Ed.).
- George, C.F., Orme, M.L., Buranapong, P., Macerlean, D., Breckenridge, A.M. and Dollery, C.T.: *J. Pharmacokin, Biopharm.*, 4(1):17, 1976.
- Davies, D.S., George, C.F., Blackwell, E., et al.: *Br. J. Clin. Pharmacol.*, 1:129, 1974.
- Gibaldi, M.: *Biopharmaceutics and Clinical Pharmacokinetics*. Lea and Febiger, Philadelphia, 1979 (1st Ed.).
- Furesz, S.: *Antibiot, Chemother.*, VIII(9):446, 1958.
- Downer, H.D., Galloway, R.W., Horwich, L. and Parke, D.V.: *J. Pharm. Pharmacol.*, 22:479, 1970.
- Åsberg, M., Evans, D.A.P. and Sjöqvist, F.: *Chem.-Biol. Interactions*, 3:238, 1971.
- Ochs, H.R. and Kölle, E.U.: *Drug, Dev. Eval.*, 9:225, 1983.

(List continued on next page.)

OTHER PUBLICATIONS

- Varro, V.: *Ther. Hung.*, 15:3, 1967.
- Ramsch, K. D., "Zur Pharmakokinetik von Nifedipin", *S., 4. Heft* 4:55-61 (1981).
- Urquhart, J., "Controlled-Release Pharmaceuticals", APS Section of Pharmacology and Toxicology at the 27th National Meeting of the Academy of Pharmaceutical Sciences, Kansas City, MO (11/79).
- Cabana, B., "Regulatory Consideration in Transdermal Controlled Medication", *Drug Development Industrial Pharmacy*, 9(4), 707-724 (1983).
- Kala and Dittgen, "In Vitro and In Vivo Availability of the Active Principles From Acrylic Polymer-Based Capsules", pp. 7-17.
- Brunnengraeber, *Chem. Abstr.* 76 #27955W-Drug Filled Capsules.
- Imhof, *Chem. Abstr.* 85 #130521m "Pharmaceutical Preparations for Prophylactic and Therapeutic Treatment of Coronary Heart Disease"
- Dittgen, *Chem. Abstr.* 85 #198123p "Preparation and In Vitro Testing of Polyacrylate-Based Bead-Polymerizates Containing Pharmaceutically Active Ingredients".
- Dittgen, *Chem. Abstr.* 87 #189376n "Preparation an In Vitro Testing of Polyacrylate-Based Polymers Containing . . ."
- Dittgen, "Poliakrilat alapu gyogyszerhatoanyag-tartalmu gyongy-polimerizatumok eloallitasa es in vitro vizsgalata", 20. evfolyam 7 szam.
- Miyata, *Chem. Abstr.* 86 #65806n "Polynuclear Complex Compound".
- Corneille, *Chem. Abstr.* 87 #206519f "Pharmaceutically Administratable Form of Vincamine and Its Derivatives".
- Galeazzi, *Chem. Abstr.* 88 #11845x "The Effect of an Antacid on the Bioavailability of Indomethacin".
- Buchanan, *Chem. Abstr.* 88 #146179d "Assessment of Antithrombotic Drugs Ex Vivo and In Vivo.
- Dittgen, *Chem. Abstr.* 89 #12078g "Drug Release From Embedding Forms Based on Polyacrylate".
- Dittgen, *Chem. Abstr.* 89 #30644t "Study on in Vitro Drug Release From Polyacrylate-Based Bead Polymerizates".
- El-Sabbagh, et al., *Chem. Abstr.* 89 #169017j "Solubilization of Indomethacin".
- Gittgen, et al., *Chem. Abstr.* 90 #76473k "In Vitro and In Vivo Availability of the Active Principles From Acrylic Polymer-Based Beads".
- Prugnand, *Chem. Abstr.* 91 #18147e "Composition Containing Pyrimidopyrimidine Derivative and Acetylsalicylic Acid".
- Vignon, et al., *Chem. Abstr.* 92 #82302m "Bioavailability of Indomethacin. Study of a Delayed-Release Formula".
- Panoz, et al., *Chem. Abstr.* 93 #225639k "Oral Formulations With Programmed Action".
- Volpi, et al., *Chem. Abstr.* 94 #36188x "Therapeutic Doses and Physicochemical Constants of Bases and Acids".
- Kawata, et al., *Chem. Abstr.* 94 #127383y "Continuously Releasing Pharmaceutical Preparation of a Solid Drug Material".
- Astier, et al., *Chem. Abstr.* 95 #225564y "Relative Bioavailability of a Sustained Release Indomethacin, Compared to Conventional Immediate Action Preparation".
- Elan Reviews "Evaluation of Antibiotic Therapy, A New Perspective (c. 1980).
- Panoz, "Innovation and Creativity in The Design of New Pharmaceutical Disage Forms", 1981 Symposium.
- Corrigan, et al., "Development of a Controlled Absorption Ouinidine Drug Delivery System", publ. *Controlled Release Delivery Systems*, Roseman & Mansdorf, (Chap. 12), pp. 163-167 (1983).
- Evers, "Getting Drugs Into Your Bloodstream", publ. *Technology Ireland*, (April 1982).
- Elan Brochure, 2d Ed.
- Perucca, et al., "Pharmacokinetic and Pharmacodynamic Studies With a New Controlled-Release Formulation of Propranolol in Normal Volunteers: A Comparison With Other Commercially Available Formulations", *B.J. Clin. Pharmac.* 18 at 37-43 (1984).
- Bottini, et al., "Comparative Oral Bioavailability of Conventional Propranolol Tablets and a New Controlled Absorption Propranolol Capsule", *Drug Dev. and Ind. Pharm.* 9 (8) at 1475-1493 (1983).

FIG. 2




FIG. 1




FIG. 3





FIG. 4



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.